

TABLE OF CONTENTS

PREFACE	<i>xi</i>
 CHAPTER 1	
ACCESS TO MEDICINES AND INTELLECTUAL	
PROPERTY: THE CONTRIBUTION OF THE	
WORLD HEALTH ORGANIZATION	
 I. INTRODUCTION	1
II. FIRST MANDATE OF THE WORLD HEALTH ASSEMBLY	2
III. “THE RED BOOK”	2
IV. ORIGIN OF THE TERM TRIPS “FLEXIBILITIES”	7
V. COMMISSION ON INTELLECTUAL PROPERTY RIGHTS, INNOVATION AND PUBLIC HEALTH (CIPRH)	8
VI. THE GLOBAL STRATEGY AND PLAN OF ACTION ON PUBLIC HEALTH, INNOVATION AND INTELLECTUAL PROPERTY (GSPOA)	9
VII. CONSULTATIVE EXPERT WORKING GROUP ON RESEARCH AND DEVELOPMENT: FINANCING AND COORDINATION (CEWG)	11
VIII. ADVANCES IN THE IMPLEMENTATION OF A “GLOBAL STRATEGY”	14
IX. A STEP BACKWARDS FOR THE WHO?	17
X. THE WAY FORWARD	21
ANNEX I – RELEVANT WORLD HEALTH ASSEMBLY RESOLUTIONS..	23

ANNEX II – WHO PUBLICATIONS ON INTELLECTUAL PROPERTY AND PUBLIC HEALTH	25
---	----

ANNEX III – IMPROVING ACCESS TO MEDICINES IN THAILAND: THE USE OF TRIPS FLEXIBILITIES: Report of a WHO Mission Bangkok, 31 January-6 February 2008	29
--	----

CHAPTER 2

THE RIGHT TO HEALTH AND MEDICINES: THE CASE OF RECENT NEGOTIATIONS ON THE GLOBAL STRATEGY ON PUBLIC HEALTH, INNOVATION AND INTELLECTUAL PROPERTY

I. INTRODUCTION	55
II. THE BACKGROUND OF THE IGWG NEGOTIATIONS	56
III. THE STAKEHOLDERS	61
IV. THE CONTENT	63
V. THE PROCESS	65
A. The First Meeting in Geneva: 4-8 December 2006.....	65
B. Regional Consultations	68
C. Second Meeting: 5-10 November 2007	71
D. Continuation of the Second Meeting of the IGWG: 28 April-3 May 2008	72
E. 61st World Health Assembly: 24 May 2008	73
F. World Health Assembly: 18 May 2009	74
G. Explanation of the Vote of Some Developing Countries	76
VI. CONCLUSION	77
VII. REFERENCES.....	80
ANNEX – SIXTY-FIRST WORLD HEALTH ASSEMBLY WHA61.21	82

CHAPTER 3

RETHINKING GLOBAL HEALTH: A BINDING CONVENTION FOR R&D FOR PHARMACEUTICAL PRODUCTS

I.	INTRODUCTION	151
II.	HISTORICAL CONTEXT: WHO, AN INITIATIVE OF THE SOUTH	153
III.	ACCESS TO HEALTH AS CITIZENS' RIGHT	154
	III.1 At the National Level	154
	III.2 At an International Level	155
	III.3 WHO and the Right to Health	157
IV.	WHO OBJECTIVES AND MANDATE	159
V.	THE USE OF REGULATORY POWERS	160
VI.	A BINDING GLOBAL INSTRUMENT FOR R&D AND INNOVATION FOR HEALTH	163
	VI.1 The Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (GSPOA)	165
VII.	OBJECTIVE AND SCOPE: THE FOCUS, PRIORITY SETTING, SUSTAINABLE FINANCING AND COORDINATION OF PUBLIC R&D FOR PHARMACEUTICAL PRODUCTS	166
VIII.	THE PRINCIPLES	166
IX.	POSSIBLE MAIN COMPONENTS OF A BINDING GLOBAL INSTRUMENT FOR R&D AND INNOVATION FOR HEALTH	167
	IX.1 Some Possible Elements of a Binding Global Instrument for R&D and Innovation for Health	168
X.	WHO AUTHORITY TO ADOPT BINDING GLOBAL INSTRUMENTS, INTERNATIONAL CONVENTIONS OR TREATIES	169

XI.	CONCLUSIONS AND RECOMMENDATIONS	169
	REFERENCES	171
	ANNEX 1 – THE WHO FRAMEWORK CONVENTION ON TOBACCO CONTROL.....	176
	ANNEX 2 – THE INTERNATIONAL HEALTH REGULATIONS	179
	ANNEX 3 – INTERNATIONAL CODE OF MARKETING OF BREAST-MILK SUBSTITUTES	182

CHAPTER 4

PUBLIC-PRIVATE PARTNERSHIPS IN GLOBAL HEALTH: PUTTING BUSINESS BEFORE HEALTH?

I.	INTRODUCTION	185
II.	SOME CONCEPTS, DEFINITIONS AND VISION	188
	II.1 PPPs	188
	II.2 Views of the UN Global Compact	188
	II.3 PPPs in Public Health	189
	II.4 Different Types of PPPs.....	194
	II.5 PDPs	195
III.	CONTRIBUTION VERSUS RISKS OF PPPS AND PDPs IN HEALTH.....	202
	III.1 Guidelines on Interaction with Commercial Enterprises.....	203
IV.	MULTILATERALISM, PPPS AND WHO REFORM	205
V.	ARE PPPS AND PDPs THE ONLY SOLUTION?.....	209
VI.	CONCLUSIONS	211